|
|
|
27.02.26 - 12:36
|
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters′ Option to Purchase Additional Shares (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026.
The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre‑funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of their option to purchase additional shares of stock in the offering. All shares and pre-funded warrants were sold by Zura.
Gross proceeds from the offering were approximately $144 million, before deducting underwriting discounts and commissions and other offering e...
|
|
|
|
|
|
|
|
|
27.02.26 - 06:15
|
Research: M Stanley's H-shr Focus List (Table) (AAStocks)
|
|
|
Stocks | Potential Upside from Target PricesAlibaba (BABA.US) | 17.8%CHALCO (601600.SH) | +20.7%CATL (300750.SZ) | 33.3%DUALITYBIO-B (09606.HK) | 41.8%ESPRESSIF (688018.SH)| 30.7%HKEX (00388.HK) | 22%HKT-SS (06823.HK) | 7.1%NARI (600406.SH) | 0.9%PING AN (02318.HK) | 22.6%INOVANCE TECH (300124.SZ) | 25.7%SINOMA SCI & TECH (0......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 13:03
|
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates (Business Wire)
|
|
|
– Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025
– Zocilurtatug pelitecan (zoci) on track to become Zai Lab's first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026
– Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE)
– Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026
Conference call and webcast today, February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT)SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates.
“20...
|
|
|
|
|
|
|
|
|
|
|
25.02.26 - 12:36
|
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase 1,800,000 Class A ordinary shares at a price to the public of $6.249 per pre-funded warrant, which equals the public offering price per Class A ordinary share, less the $0.001 exercise price of each pre-funded warrant. In addition, Zura has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 Class A ordinary shares at the public offering price, less underwriting discounts and commissions. All of the Class A ordinary shares and...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
